Cargando…
Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an...
Autores principales: | Lefebvre, Eric, Moyle, Graeme, Reshef, Ran, Richman, Lee P., Thompson, Melanie, Hong, Feng, Chou, Hsin-l, Hashiguchi, Taishi, Plato, Craig, Poulin, Dominic, Richards, Toni, Yoneyama, Hiroyuki, Jenkins, Helen, Wolfgang, Grushenka, Friedman, Scott L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922569/ https://www.ncbi.nlm.nih.gov/pubmed/27347680 http://dx.doi.org/10.1371/journal.pone.0158156 |
Ejemplares similares
-
Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016) -
Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017) -
Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015) -
Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022) -
Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy
por: Kwiatkowski, Klaudia, et al.
Publicado: (2020)